DouglasYeeMD

Oncology • Minneapolis, MN

Breast Cancer, Hematologic Oncology

Professor of Medicine Director, Masonic Cancer Center, University of Minnesota

Join to view full profile

Dr. Yee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yee's full profile

Already have an account?

Office
Masonic Cancer Center, University of Minnesota
420 Delaware Street SE
Minneapolis, MN 55455
Phone+1 612-626-8487

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of North Carolina HospitalsResidency, Internal Medicine, 1981 - 1985
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1981

Certifications & Licensure

MN State Medical License 1999 - 2025
TX State Medical License 1989 - 2007
NC State Medical License 1984 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2006 Jul 01
Terminated
Phase 2
CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery
Withdrawn
Phase 1
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2008 Jul 01
Withdrawn
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer Start of enrollment: 2017 May 04
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

40 citations
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Mark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W Sayaman, Derrick Renner
Cancer Cell. 2023-06-12
128 citations
FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter.
Susan K. Durham, Adisak Suwanichkul, Ann O. Scheimann, Douglas Yee, James G. Jackson
Endocrinology. 1999-07-01
112 citations
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Rosa I Gallagher
Cancer Cell. 2022-06-13

Lectures

The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast Cancer
American Society of Clinical Oncology(ASCO), Chicago, Illinois - 8/9/2013
The DNA Cytosine Deaminase APOBEC3B Promotes Tamoxifen Resistance in ER-Positive Breast Cancer
American Society of Clinical Oncology(ASCO), Los Angeles, California - 8/16/2013

Press Mentions

Meet the Group Making Cancer Trials More Equitable in MinnesotaNovember 13th, 2024
What Black Women Should Know on Metastatic Breast Cancer Awareness DayOctober 16th, 2024
What Black Women Should Know About Metastatic Breast CancerOctober 14th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member